Novo Nordisk A/S vs ASML Holding NV
A head-to-head of Novo Nordisk A/S (NVO) and ASML Holding NV (ASMLF) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | NVO | ASMLF |
|---|---|---|
| Market Cap | $182.56B | $541.44B |
| P/E (TTM) | 1.75 | 44.97 |
| Forward P/E | 12.24 | 40.16 |
| P/S | 0.59 | 16.07 |
| P/B | 0.92 | 22.44 |
| EV/EBITDA | 8.12 | 38.65 |
| Dividend Yield | 29.22% | 0.55% |
| Profit Margin | 33.14% | 30.86% |
| Gross Margin | 80.98% | 52.83% |
| Operating Margin | 41.30% | 34.60% |
| Revenue Growth (YoY) | -7.63% | +13.25% |
| FCF Yield | 15.88% | 1.65% |
| Debt / Equity | 67.49 | 12.99 |
| Current Ratio | 0.80 | 1.36 |
Share:
Compare Novo Nordisk A/S with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.